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Optogenetics is an extremely powerful tool for selective neuronal activation/inhibition
and dissection of neural circuits. However, a limitation of in vivo optogenetics is that
an animal must be tethered to an optical fiber for delivery of light. Here, we describe
a new method for in vivo, optogenetic inhibition of neural activity using an internal,
animal-generated light source based on firefly luciferase. Two adeno-associated viruses
encoding luciferase were tested and both produced concentration-dependent light after
administration of the substrate, luciferin. Mice were co-infected with halorhodopsin- and
luciferase-expressing viruses in the striatum, and luciferin administration significantly
reduced Fos activity compared to control animals infected with halorhodopsin only.
Recordings of neuronal activity in behaving animals confirmed that firing was greatly
reduced after luciferin administration. Finally, amphetamine-induced locomotor activity
was reduced in halorhodopsin/luciferase mice pre-injected with luciferin compared to
controls. This demonstrates that virally encoded luciferase is able to generate sufficient
light to activate halorhodopsin and suppress neural activity and change behavior. This
approach could be used to generate inhibition in response to activation of specific
molecular pathways.
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INTRODUCTION
The use of optogenetics has increased dramatically in the last
several years, largely due to its applicability to studies span-
ning from single-cell electrophysiology to whole-animal behav-
ior. In vivo techniques are particularly powerful as they allow
for control of behavior with manipulation of a single neuron
subtype (Witten et al., 2010; Narayanan et al., 2012). How-
ever, one restriction to in vivo optogenetics is the necessity
of an external light source (laser or LED) that must be con-
nected to the animal via indwelling cannula. While optical rotary
joints allow for relatively free movement within an open-topped
behavioral apparatus, home-cage illumination or any structure
with an enclosed top are not feasible. Recently, two groups
have introduced wireless optogenetics approaches, where the
signal/power is sent to a headstage containing indwelling LEDs
(Wentz et al., 2011; Kim et al., 2013). While this solves the
problem of tethering, specialized equipment is needed to both
send the signal and to receive it, which could add a signifi-
cant cost to the setup and may require significant expertise to
implement.
One potential solution is to eliminate the need for an exter-
nal light source by creating a system in which the animal
produces its own light. This can be accomplished by leverag-
ing light-producing proteins that exist in nature, in a similar
fashion to the opsins that are sensitive to light. These pro-
teins can be expressed using viral systems in a way similar to
the opsins, to internally generate light. Firefly luciferase is one
such protein, and it produces yellow-red light in the presence
of its substrate, luciferin (Nakatsu et al., 2006). Mammalian
systems readily tolerate luciferase and luciferin, and this sys-
tem has been used in vivo to measure gene activity and track
labeled cells (Contag, 2007). Notably, the emission spectrum of
firefly luciferase overlaps highly with the action spectrum of
halorhodopsin (Zhang et al., 2007), a bacterially derived, amber
light photoreceptive chloride pump that inhibits neural activity.
This suggests that with sufficient light output, luciferase could
serve as a light source that would activate halorhodopsin and
inhibit neural activity, eliminating the need for an external light
source, and establishing a genetically-encoded light generating
system. While this reduces control over timing, it would allow
for production of light in response to specific cellular signals.
Here, we show that luciferin/luciferase and halorhodopsin are
sufficient to reduce neural activity in vivo and disrupt basic
behaviors, establishing a proof-of-principle for luciferase-based
inhibition.
MATERIALS AND METHODS
ANIMALS
Eighteen male C57Bl/6 mice were used for these studies. Animals
were group housed, with the exception of the two mice used for
electrophysiology that were single-housed after surgery. Animals
were kept on a 12 h light/dark cycle and provided standard chow
and water ad libitum, and all animal procedures were performed
in accordance with the protocol approved by the Institutional
Animal Care and Use Committee (IACUC).
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VIRAL PREPARATION AND SURGERY
Viral production for the EF1a-luciferase construct was accom-
plished using a triple-transfection, helper-free method, and puri-
fied as described in detail previously (Hommel et al., 2003). To
generate the EF1a-luciferase construct, a flox-ChR2 construct
(AAV2-DIO-ChR2-eYFP, UNC viral core) was restriction digested
outside of the asymmetric loxP sites using NheI and AscI restric-
tion enzymes, and a cassette containing luciferase was inserted.
AAV5-hSyn-eNpHR3.0-eYFP (halorhodopsin) and AAV2-CMV-
luciferase virus were purchased from University of North Carolina
viral core.
For surgery, animals were anesthetized with 10% ketamine/
1% xylazine (10 ml/kg body weight) and placed in a stereo-
taxic frame (Stoelting). After craniotomy, mice were injected
with AAV2-luciferase (0.5 uL, EF1a or CMV) and/or AAV2-
halorhodopsin (0.5 uL) into the dorsal striatum (AP: +0.7, ML±
1.75, DV−3.5 from bregma). For the electrophysiological studies,
animals were injected with virus into the ventral striatum (AP:
+1.4, ML −0.7, DV −4.5 from bregma) before placement of the
electrode. A 16-channel array of microwire electrodes (Tucker-
Davis Technologies, TDT) was placed in the same craniotomy.
A ground wire attached to the array was placed above the dura
through a burr hole in the opposite hemisphere. Arrays were
composed of 16 Teflon-coated, 50 µm tungsten wires arranged in
an 8 × 2 configuration with each electrode spaced by 250 µm. In
vitro impedance of the electrodes is 100–300 kohms. Electrodes
were affixed to the skull with cyanoacrylate (“Metabond”) and
methyl methacrylate (dental cement) and two screws placed over
the parietal bones. In total, headstages weighed approximately
2.5 g and were well-tolerated by animals.
IN VITRO LIGHT ASSAY
HT-1080 cells were cultured using standard media, and were
infected with either no virus or increasing dilutions of the EF1a
or CMV luciferase virus (1:100, 1:500, 1:2500). Twenty four
hours after infection, cells were harvested and combined with
a luciferase based light detection kit (Stratagene). After adding
luciferin, the cells were placed in a luminometer (Berthold) and
light was detected, expressed as Relative Light Units per second
(RLU/s).
IN VIVO ELECTROPHYSIOLOGY
After approximately 2–3 weeks of recovery to ensure optimal
viral expression and neuronal signal, freely moving animals were
connected to the recording system while in a behavioral box (Med
Associates). After 1 h of habituation, neurons were recorded for
a 10 min baseline and then given an IP injection of either saline
or luciferin (150 mg/kg). Recordings were continued for 1 h post-
injection. Plugging and unplugging from the electrode cables was
performed under isofluroane anesthesia to minimize stress on the
animals.
Neural ensemble recordings were made using a multichannel
acquisition processor (MAP) from TDT. Putative single neu-
ral units were identified on-line using an oscilloscope and an
audio monitor. The TDT off-line sorter was used to analyze
the signals and to remove artifacts due to cable noise. Principal
component analysis (PCA) and waveform shape were used for
spike sorting (Sears et al., 2010). Single units were identified as
having: (1) consistent waveform shape; (2) separable clusters in
PCA space; (3) average amplitude estimated at least three times
larger than background activity; and (4) a consistent refractory
period of at least 2 ms in interspike interval histograms. Those
units identified on-line as potential single units that did not
meet these criteria off-line were not included in this analysis.
Graphical exploratory analysis of neural activity and quantitative
analysis of basic firing properties (firing rate, interspike intervals)
were analyzed using custom routines for MATLAB. For each
well isolated neuron, post-injection firing rates were normalized
to mean pre-injection firing rates (in the 10 min immediately
preceding drug injection) and binned (60 s bins). Activity was
then compared between neurons recorded in luciferin and saline
conditions.
LOCOMOTOR ACTIVITY
After 2–3 weeks of recovery after viral surgery, animals were pre-
habituated for 90 min to locomotor chambers that consisted of a
mouse cage-bottom, without bedding, inside of an infrared one-
dimension beam-break array (Med Associates). On test day, ani-
mals were again habituated to the chambers for 90 min. Animals
were then briefly removed and injected with luciferin (150 mg/kg)
and returned to the chamber. Twenty minutes later animals were
injected with amphetamine (2.5 mg/kg) and returned to the
chamber for 90 min. Locomotor counts were calculated as the
number of consecutive beam-breaks in the chamber, and these
counts were made throughout the entire testing period.
IMMUNOFLUORESCENCE
Animals that performed the locomotor behavioral tests were
allowed to recover for at least 2 weeks before sacrifice. On the
day of sacrifice, animals were injected with luciferin (150 mg/kg),
followed 20 min later by injection of pentylenetetrazol (PTZ,
45 mg/kg) to induce seizure activity. Animals were observed for
signs of seizure (as confirmation of a general increase in neural
activity) and 90 min after PTZ injection were deeply anesthetized
and intracardially perfused with 4% paraformaldehyde. The brain
was removed and post-fixed overnight in paraformaldehyde, and
after immersion in sucrose for cryoprotection, 40 µm sections
were made on a freezing microtome, and stored in 1 × PBS with
0.01% sodium azide to prevent bacterial growth. Immunohisto-
chemistry was performed according to methods described previ-
ously (Sears et al., 2010). Staining for Fos (Rabbit anti-cFos; Santa
Cruz; 1:500) or Luciferase (Goat anti-luciferase; Promega; 1:500)
with secondary antibodies (Alexa or 555 and 633; Invitrogen/Life
Sciences) was performed in 3% normal donkey serum and 0.3%
Triton-X 100. Tissue was visualized and images were captured
using a fluorescent microscope (Zeiss) using standard FITC and
TRITC filters or using a confocal microscope (Olympus). Fos
labeling was quantified by standard threshold settings in ImageJ
(NIH) over matched areas on one or more (averaged) sections per
animal.
STATISTICS
Comparisons were made using one-way and two-way ANOVA,
and unpaired, two-tailed t-tests where appropriate. Differences
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in means were considered significant if p-values were <0.05, and
were calculated using Graphpad Prism 5.0 and 6.0. Error bars
represent s.e.m.
RESULTS
Because the emission spectrum of firefly luciferase overlaps
considerably with the action spectrum of halorhodopsin
(Figure 1A), we reasoned that light generation from luciferase
should activate these chloride pumps to drive hyperpolarization
of membranes. Towards this goal, we designed an adeno-
associated viral construct containing the firefly luciferase
gene with an EF1a promoter, in addition to testing a virus
containing the CMV promoter (UNC viral core, Figure 1B).
To assess the ability of these constructs to generate light in
vitro, we infected HT-1080 cells with varying dilutions. After
24 h of infection, cells were assayed for light production after
treatment with luciferin. With both viruses, light production
was dilution-dependent, with higher concentration of virus
producing more light, as expected (Figure 1C, CMV, F(3,12) =
113.7, P < 0.0001; EF1a, F(3,19) = 12.01, P = 0.0001). The
CMV-luciferase generated approximately 6-fold more light
(0.78 order of magnitude) than the EF1a-luciferase, likely due
FIGURE 1 | Virally expressed luciferase generates light. (A) Emission and
activation spectra for firefly luciferase (green) and halorhodopsin (amber),
respectively. Note the high degree of overlap between the two. (B)
Schematics of the firefly luciferase viral constructs used. (C) Light output (in
Relative Light Units per second) of the two viral constructs after 24 h of
infection at various dilutions of virus in HT-1080 cells (n = 4 per group for CMV,
n = 5,6,5,7 for 1:100, 1:500, 1:2500, no virus respectively for EF1a). * P <
0.05, ** P < 0.01.
FIGURE 2 | Luciferase and halorhodopsin inhibit cFos activity. (A)
Micrographs depicting the dorsal striatum of an animal infected with
luciferase (red) and halorhodopsin (green, lower), or halorhodopsin alone
(upper). cFos immunofluorescence 90 min after PTZ injection is in blue. (B)
Quantification of cFos in the dorsal striatum of luciferase/halorhodopsin and
halo only animals 90 min after PTZ injection (n = 6 striatal samples from four
animals). (C) Schematic drawing of the rostro-caudal distribution of luciferase,
halorhodopsin, and cFos in one animal. Note that in general, there is very little
cFos immunofluorescence where both luciferase and halorhodopsin are
expressed. ** P < 0.01.
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to differences in titer between the viruses. Nonetheless, these
results suggest that both constructs are capable of producing
light.
To test whether luciferase-induced light was sufficient to
inhibit neural activity in vivo using biochemical markers, we
infected mice in the dorsal striatum with either a combination of
the EF1a-luciferase and halorhodopsin, or halorhodopsin alone.
After recovery and behavioral testing (described below), animals
were pre-treated with luciferin (150 mg/kg) 20 min prior to
injection with PTZ, a drug known to induce seizures and cFos
expression throughout the striatum. This dose of luciferin was
derived from literature showing luciferase activity for 1–2 h
after injection (Burgos et al., 2003; Cordeau and Kriz, 2012).
Ninety minutes after PTZ injection, animals were sacrificed and
processed for cFos immunofluorescence. Control animals injected
with halorhodopsin alone showed a robust Fos induction in the
dorsal striatum, and this response was reduced when luciferase
was co-expressed with halorhodopsin (Figures 2A, B, t10 = 5.78,
P = 0.0002). We mapped the extent of both viral expression
and cFos induction (Figure 2C), and found a large volume of
FIGURE 3 | Individual neurons show decreased activity during
luciferase-based illumination. (A) Schematic showing the rostral-caudal
position of the 16-channel electrode for two animals (blue and red). Solid
vertical lines represent the first and last pair of electrodes in the 2 × 8
array (modified from Paxinos and Franklin, 2004, values are AP distance
from bregma in mm). (B) Left, two neurons sorted by principle component
analysis (PCA) in one channel. Axes refer to the different principle
components. Right, the two waveforms corresponding to the PCA. (C)
Top, rastors depicting action potentials for neurons in the saline (gray, n =
11) and luciferin (orange, n = 12) injected conditions over the timecourse
of the experiment. Bottom, normalized firing rate over the same period.
Note that while the saline condition remains around the baseline, luciferin
injection produces a prolonged decrease in firing. (D) Left, total number of
action potentials during the baseline period (10 min). Right, total number
of action potentials after injection (60 min, n = 11,12 for saline and
luciferin, respectively). (E) Top, rastors depicting action potentials for the
luciferin-injected condition (n = 6). Bottom, normalized firing rate over the
course of the experiment. ** P < 0.01.
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viral spread and a striking reduction in cFos in regions with
expression of both viruses. These results suggest that luciferase
is able to produce light in vivo in at sufficient power to activate
halorhodopsin and affect neural activity.
To further demonstrate the efficacy of this inhibitory
strategy in real time, we implanted mice with 16-channel
electrodes for in vivo electrophysiology, in addition to the
luciferase/halorhodopsin dual infection, into the ventral striatum
(Figure 3A). This allowed us to directly monitor neural activity as
a function of luciferin/luciferase-driven light. Following acclima-
tion to the chamber, animals were given a 10 min baseline period,
after which they were injected with either luciferin (150 mg/kg),
or saline on alternating, counterbalanced days. Units were sorted
by PCA based on waveform (Figure 3B), and firing was nor-
malized to the baseline period. Compared to saline injection,
luciferin produced a marked decrease in firing that began soon
after injection (Figure 3C, significantly different from normalized
firing = 1 at 9 min, one-sample t-test, P < 0.01) and lasted at
least 60 min (F(69,1449) = 3.61, P < 0.0001, interaction of time
by treatment). Summing total action potentials shows that during
the baseline period (−10–0 min) there was no difference in spikes
(t21 = 1.47, P = 0.16), while there was a dramatic decrease in
spiking in the 60 min after luciferin injection compared to saline
(Figure 3D; t21 = 3.03, P = 0.006). Because we did not see a return
to baseline, a third animal was implanted as described above and
injected with a 10-fold lower dose of luciferin (15 mg/kg). Again,
we saw a characteristic decrease in firing, but at this dose the
normalized firing returned to baseline at 60 min (Figure 3E).
This shows that neural activity can be attenuated rapidly and in
a sustained fashion using this luciferase-based approach.
Finally, to demonstrate that these decreases in activity
have functional behavioral consequences, animals with bilat-
eral, dorsal striatal injections of either luciferase/halorhodopsin
or halorhodopsin alone were tested in a locomotor activity
paradigm after amphetamine treatment. Animals were habit-
uated to the locomotor boxes (90 min) on the testing day,
and were then injected with luciferin (150 mg/kg) 20 min
before injection of amphetamine (2.5 mg/kg, Figure 4A). While
there were no differences in the last 20 min of the habitua-
tion period or the 20 min following luciferin injection, ani-
mals with luciferase/halorhodopsin expression were unaffected by
amphetamine for 30 min after amphetamine injection, compared
to controls whose activity increased as expected (Figure 4B;
F(5,50) = 2.83, P = 0.025). After 30 min, the experimental animals’
activity increased slightly and matched control activity for the
remainder of the test period. These findings corroborate the
neural activity data, and show that neural inhibition using this
approach can have profound effects on behavior.
DISCUSSION
In the present study, we have demonstrated that a combination
of luciferase and halorhodopsin viruses can be used together to
suppress neural activity without an external light source. This
hybrid, chemical-optogenetics approach requires administration
of luciferin, but is otherwise noninvasive and could be easily
adapted to any testing apparatus or environment. Potentially,
luciferin could be delivered via minipump for chronic exposure.
FIGURE 4 | Amphetamine induced locomotor activity is attenuated
with luciferase-based illumination. (A) Timeline of the behavioral test.
(B) Locomotor activity during the last 20 min of baseline, 20 min of luciferin
alone, and 90 min after amphetamine (n = 6 per group). * P < 0.05 for
30 min following amphetamine injection, two-way ANOVA, interaction of
time and treatment.
Our initial studies have shown that a single injection of luciferin
can inhibit neurons for at least 1 h in vivo, and this correlates
strongly with our behavioral measures. Further, this approach
is adaptable to cell-type specific targeting using Cre-lox systems
with halorhodopsin.
In principle, this technique resembles the DREADD (Designer
Receptors Exclusively Activated by Designer Drugs) system for
inactivating neurons (Armbruster et al., 2007), but there are
at least two important differences. First, because this uses a
combination of chemogenetics and optogenetics, one could
also use traditional optogenetic illumination in these animals
if needed. This makes the present system more adaptable to
current optogenetic approaches and allows a single set of ani-
mals to be used with both external and internal light deliv-
ery. Also, because the halorhodopsin is a chloride pump, its
inhibitory effects are rapid and direct with behavioral effects
lasting <1 h. This is in contrast to the DREADD system, which
uses G-protein coupled receptors whose behavioral effects last
∼8 h after agonist (clozapine N-oxide) injection (Alexander
et al., 2009; Carter et al., 2013). While the onset time for
DREADD stimulation can also be rapid (e.g., Sasaki et al.,
2011; Garner et al., 2012), the present data suggests that
the luciferase system may provide a shorter time window of
effect.
The use of a genetically encoded luciferase also allows potential
application of this system as part of an inhibitory feedback loop in
response to activation of a specific signaling pathway. Luciferase
could be put under direct transcriptional regulation of a known
pathway, or potentially modified to allow for post-translational
activation, allowing for dynamic response that reflects activa-
tion of a signaling cascade. Although this approach would still
require injection of luciferin, it could be useful for functional
identification of pathways associated with addiction, or other
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diseases where aberrant neuronal activation contributes to disease
pathology.
In sum, this endogenous light-production technique adds to
the expanding toolkit that can be applied to optogenetic control
of behavior. Uniquely, this approach allows neuronal inhibi-
tion without tethering or specialized equipment, expanding the
breadth of behavioral experiments that can be performed.
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